Pursuant to provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, read together with the circulars and notification ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental's board approved its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025 on May 30, 2025. Standalone revenue from operations rose strongly to Rs. 6,712.58 lakhs from Rs. 4,403.68 lakhs (up ~52%), while standalone profit after tax grew to Rs. 256.58 lakhs from Rs. 189.70 lakhs (up ~35%). On a consolidated basis (including subsidiaries Evagrace Pharma, Ritz Formulations, Sungrace Pharma, Azillian Healthcare and JV Medico Lab), revenue rose to Rs. 9,601.52 lakhs and PAT to Rs. 505.73 lakhs (up ~43%). The statutory auditor V. Goswami & Co issued an unmodified (clean) opinion on both sets of results. The board also appointed Agarwal & Mehta as Secretarial Auditor for five years (FY26–FY30) and re-appointed MJV & Co as Internal Auditor for FY26.
A clean audit report, strong double-digit revenue and profit growth across both standalone and consolidated books is a positive signal for shareholders. The sharp rise in long-term borrowings (from Rs. 80 lakhs to Rs. 1,277 lakhs standalone) is worth monitoring as it signals increased leverage, though operating cash flow remains healthy.